ArticleJAMA network open2025

Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.

Lindsey Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.